REGENERX BIOPHARMACEUTICALS
RGN
RGN was delisted on the 22nd of December, 2010.
3 hedge funds and large institutions have $94K invested in REGENERX BIOPHARMACEUTICALS in 2017 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
71% more capital invested
Capital invested by funds: $55K → $94K (+$39K)
50% more funds holding
Funds holding: 2 → 3 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PTC
Philadelphia Trust Company
Philadelphia,
Pennsylvania
|
+$44K |
Top Sellers
RGN Hedge Fund Activity: Q1 2017 in Review
3 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in REGENERX BIOPHARMACEUTICALS (RGN) for Q1 2017, worth a combined $94K — up 71% from $55K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new RGN positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Philadelphia Trust Company, opening a new position worth an estimated $44K.
- 3 institutional investors held REGENERX BIOPHARMACEUTICALS (RGN) as of Q1 2017, up from 2 in Q4 2016.
- Funds reported $94K of REGENERX BIOPHARMACEUTICALS stock for Q1 2017, up 71% quarter-over-quarter.
- 1 fund opened new REGENERX BIOPHARMACEUTICALS positions in Q1 2017 and 0 closed out, a net change of +1 holder.
- The largest REGENERX BIOPHARMACEUTICALS buyer in Q1 2017 was Philadelphia Trust Company, an estimated $44K added.
Based on aggregated 13F filings for Q1 2017.